Asset Details
Do you wish to reserve the book?
Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01
Do you wish to request the book?
Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01
2014
Overview
The development of new low cost inactivated polio virus based vaccines (IPV) is a high priority, and will be required to eradicate polio. In addition, such a vaccine constitutes the only realistic polio vaccine in the post-eradication era. One way to reduce the cost of a vaccine is to increase immunogenicity by use of adjuvants. The CAF01 adjuvant has previously been shown to be a safe and potent adjuvant with several antigens, and here we show that in mice IPV formulated with CAF01 induced increased systemic protective immunity measured by binding and neutralization antibody titers in serum. CAF01 also influenced the kinetics of both the cellular and humoral response against IPV to produce a faster, as well as a stronger, response, dominated by IgG2a, IgG2b, and IgG2c isotypes as well as IPV specific T cells secreting IFN-γ/IL-2. Finally, as intestinal immunity is also a priority of polio vaccines, we present a vaccine strategy based on simultaneous priming at an intradermal and an intramuscular site that generate intestinal immune responses against polio virus. Taken together, the IPV-CAF01 formulation constitutes a new promising vaccine against polio with the ability to generate strong humoral and cellular immunity against the polio virus.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Adjuvants, Immunologic - administration & dosage
/ Adjuvants, Immunologic - pharmacology
/ Animals
/ Antibodies, Viral - immunology
/ Antigens
/ Dose-Response Relationship, Immunologic
/ Female
/ Immunity
/ Immunity, Cellular - drug effects
/ Immunity, Cellular - immunology
/ Immunoglobulin A - immunology
/ Immunoglobulin G - metabolism
/ Isotypes
/ Kinetics
/ Poliovirus Vaccine, Inactivated - administration & dosage
/ Poliovirus Vaccine, Inactivated - immunology
/ Priming
/ Suidae
/ Vaccines
/ Viruses
